Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IIIb riociguat study in inoperable or persistent/recurrent CTEPH
NL-OMON38503Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Bayer. Primary endpoints: Safety and tolerability and Clinical effects. Started Sep 2013; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON38503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38503.